Dr Reddy's Laboratories and Lupin are recalling products in the US market due to labelling and manufacturing errors, respectively, according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA) said a US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market. Princeton-based Dr Reddy's Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said. "The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL," it added. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted. As per the USFDA, a Class I recall pertains to .

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

16 Apr 2025

1171.30

-0.98%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

pdf

Dr. Reddy's Laboratories Ltd.

15 Apr 2025

1171.30

-0.98%

Dr. Reddy's Share Price Rises 3% As Firm Dismisses Report On Job Cuts

NDTV Profit

The pharma major called a Business Standard report on senior-level exits and cost trimming factually incorrect'.

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr Reddy's Denies Plans To Implement 25% Workforce Cost Reduction

NDTV Profit | 14 Apr 2025 1 more

Dr. Reddy's Laboratories Ltd.

14 Apr 2025

1171.30

-0.98%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

pdf

Dr. Reddy's Laboratories Ltd.

09 Apr 2025

1171.30

-0.98%

US tariffs on Pharma: Dr Reddy's to Sun Pharmacan Indian drugmakers escape Trump's tariff tantrums?

livemint

US tariffs on Pharma: India currently levies up to 10% import duties on drugs imported from the US with several drugs having lower duty of 5% while around 150 drugs are exempted from duties.

Dr. Reddy's Laborato.. has an average target of 1347.12 from 10 brokers.

Dr. Reddy's Laboratories Ltd.

09 Apr 2025

1171.30

-0.98%

Kyndryl partners with Dr Reddy's to automate IT ops with AI-powered platform

Business Line

The initiative will implement a Zero Touch IT Operations model using Kyndryl's Dual Model IT Ops framework, targeting a 60% reduction in manual interventions

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

07 Apr 2025

1171.30

-0.98%

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

Business Standard

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Dr. Reddy's Laboratories Ltd. is trading below its 100 day SMA of 1219.4

Is Dr. Reddy's Laboratories Ltd. worth buying?

501 Votes:

Buy 78.04%

Sell 12.18%

Hold 9.78%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf

52W Low on Apr 07, 2025

Dr. Reddy's Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Dr. Reddy's Laboratories Ltd. from all sources in a single place.